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The vagina, as a drug delivery site, offers certain unique features that can be ex-
ploited in order to achieve desirable therapeutic effects. By contrast, scientific knowledge
of the possibilities of drug delivery via the vagina is limited. The currently available vaginal
dosage forms have limitations, such as leakage, messiness and low residence time, which
contribute to poor subject or patient compliance (1).
In general, conventional controlled dosage forms delay the release of therapeutic sys-
temic levels and do not provide a rapid onset of action. To modify the release of the drug
from these systems, the surface area exposed to a fluid can be restricted by the addition
of barrier layers to one or both sides of the tablets (2–4). However, most multilayer sys-
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tems attempt to achieve a constant release rate from a tablet rather than biphasic release
of the drug. When a single constant rate of drug release does not entirely satisfy the thera-
peutic objective, a quick/slow delivery system may be an interesting alternative. This
biphasic release system can be achieved by the application of an immediate release layer
to the conventional layered matrix tablet (5). Biphasic delivery systems are designed to
release a drug at two different rates or in two different periods of time; they are either
quick/slow or slow/quick. A quick/slow release system provides an initial burst of drug
release followed by a constant rate (ideally) of release over a defined period of time. This
type of system is used primarily when maximum relief needs to be achieved quickly,
and it is followed by a sustained release phase to avoid repeated administration.
The aim of the present work was to design a mucoadhesive biphasic delivery sys-
tem of metoclopramide hydrochloride using mucoadhesive hydrophilic polymers. Me-
toclopramide hydrochloride is a potent antiemetic, effective in the treatment of nausea
and vomiting associated with cancer therapy, pregnancy, and migraine (6). Renewed in-
terest was added to this drug since it demonstrated, in addition to its antiemetic proper-
ties, in vitro and in vivo radio and chemosensitizing properties (7–9). However, the oral
bioavailability of metoclopramide hydrochloride is highly variable, showing values be-
tween 32 and 98 % due to extensive pre-systemic metabolism (10). Oral forms of meto-
clopramide hydrochloride often get vomited out before systemic absorption, particular-
ly in case of 2–3 month pregnancy, compelling parenteral or rectal administration where
both methods result in low patient compliance. In this regard, intravaginal delivery seems
to be an attractive alternative.
EXPERIMENTAL
Materials
Metoclopramide hydrochloride was obtained as a gift sample from Maan Pharma-
ceutical Private Limited, India. Ac-di-sol (crosscarmellose sodium) was kindly provided
by the Zydus Research Centre, India. Sodium starch glycolate was purchased from S. D
Fine Chemicals, India. Hydroxypropyl methylcellulose K100M (HPMC K100M) and
Ucarflock 302, were kindly provided by The Dow Chemical Company, USA. The other
ingredients were of laboratory grade.
FTIR spectroscopy
The drug, polymer and other formulation ingredients were characterized by IR spec-
troscopy using a FTIR 8400S (Shimadzu, Japan). The spectra were taken in KBr discs in
the range of 4000–500 cm–1.
Calculation of total dose and immediate part released (IPR)
The total dose of metoclopramide hydrochloride was calculated by the following
equation using available pharmacokinetics data (11):
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DR = Css ´ ClT
FX0/l = Css ´ ClT
where X0 is oral dose, l is dosing interval, F is fractional bioavailability, DR is the dosing
rate, Css is the steady state plasma concentration and ClT is total renal clearance. From
the above equation, Css for the metoclopramide hydrochloride is 3.36 mg mL–1.
IPR = (Css ´ Vd) / F = 15 mg
Dose = IPR 1 + (0.693 ´ t/t1/2) = 33 mg ~ 30 mg
where t is time up to which controlled release is required and t1/2 is the drug half-life.
Hence, the formulation should release 15 mg (50 %) of the drug within 30 minutes and
1.34 mg (4.5 %) per hour up to 12 h thereafter.
Preliminary trials of immediate release and sustained release layers
In the composition of the immediate drug release layer, two superdisintegrants, Ac-
-di-sol and sodium starch glycolate, of different concentrations were tested. Required quan-
tity of the drug, either superdisintegrant and microcrystalline cellulose were mixed thor-
oughly.
The sustained release layer was composed of the maintenance dose (15 mg) of the
drug and different hydrophilic polymers such as HPMC K100M and Ucarflock 302 along
with microcrystalline cellulose as a filler. All the ingredients were mixed thoroughly. The
quantity of powder for the sustained release layer was compressed lightly using a sin-
gle-punch tablet compression machine (Cadmach Machinery Co. Pvt. Ltd., India) equip-
ped with 13-mm round, flat and plain punches. Over this compressed layer, the required
quantity of the fast release layer was placed and compressed to obtain hardness in the
range of 5–6 kg cm–2 to form a bilayer matrix tablet. Formulation of preliminary trial
batches of the immediate release layer and sustained release layer is shown in Tables I
and II, respectively.
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Table I. Preliminary trial formulations of the immediate release layer
Ingredient G1 G2 G3 G4 G5
Metoclopramide · HCl 15 15 15 15 15
Ac-di-sol 5 6 7 – –
SSG – – – 2.5 3.5
MCC 75 74 73 77.5 76.5
Magnesium stearate 2 2 2 2 2
Talc 3 3 3 3 3
SSG – sodium stearate glycolate
MCC – microcrystalline cellulose
Optimization of sustained release layer by 32 full factorial design
A 32 randomized full factorial design was used in the present study. Two factors
were evaluated, each at three levels, and experimental trials were carried out in all nine
possible combinations. The factors were selected based on a preliminary study. Contents
of HPMC K100M (X1) and Ucarflock 302 (X2) were selected as independent variables.
The time required for 50 % drug release (t50), 80 % drug release (t80) and Q2 (drug re-
lease after 2 h) were selected as dependent variables. Dependent variables were selected
based on the drug release profile of preliminary trial batches and pharmacokinetic data
of the drug. The formulation of factorial design batches is shown in Table III. All batches
contain 15 mg metoclopramide hydrochloride, 2 % talc, 1 % magnesium stearate and q. s.
microcrystalline cellulose.
Preparation and characterization of dual component vaginal tablets
For preparation of the quick/slow (dual component) delivery system, the die of the
tablet machine was filled manually with a weighed amount of the sustained release
component. The sustained release component was then compressed and the fast release
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Table II. Preliminary trial formulations of the sustained release layer
Ingredients P1 P2 P3 P4 P5
Metoclopramide · HCl 15 15 15 15 15
HPMC K100M 150 50 75 75 100
Ucarflock 302 50 100 75 100 100
MCC 275 260 235 260 235
HPMC – hydroxypropyl methylcellulose
MCC – microcrystalline cellulose
Table III. Composition of factorial design batches
Batch code Coded level Actual value



















































X1 – amount of HPMC K100M
X2 – amount of Ucarflock 302
powder was added to the precompressed sustained release component. The formula-
tions differed in type and concentration of the polymer (HPMC K100M and Ucarflock
302) used to prepare the biphasic vaginal drug delivery. The dual component com-
pressed tablet systems were prepared by direct compression, with flat-tip punches and
13-mm diameter dies using a single punch tablet machine (Cadmach Co. Machinery Pvt.
Ltd., India). Formulation of the dual component system is shown in Table IV.
Physical tests for bilayer tablets. – Standard physical tests were performed for bilayer
matrix tablets and average values were calculated (12). Mass variation was determined
by weighing 20 tablets individually. Resistance to crushing was determined by taking 6
tablets from each formulation using a Pfizer hardness tester (Electrolab Pvt. Ltd., India).
Thickness was determined by vernier calipers. Friability was determined by weighing
10 tablets after dusting and placing them in a Roche friabilator (Campbell Electronics,
Mumbai, India).
Drug content uniformity. – Ten tablets were finely powdered and an amount equiva-
lent to 30 mg of metoclopramide hydrochloride was accurately weighed and transferred
to a 100-mL volumetric flask; 70 mL of phosphate buffer pH 4.5 was then added. The
flask was shaken for 10 min. Finally, the volume was made up to the mark with phosphate
buffer pH 4.5 (13). The mixture was then filtered and 1 mL of the filtrate was suitably di-
luted with phosphate buffer pH 4.5 to obtain a solution containing about 30 mg mL–1 of
metoclopramide hydrochloride and analyzed for metoclopramide hydrochloride content
at 272 nm using a Systronic 2201 double beam UV/Visible spectrophotometer (Shimadzu
1700 UV-Visible Spectrophotometer, Japan) and phosphate buffer pH 4.5 as blank.
In vitro dissolution studies
The release rate of metoclopramide hydrochloride from the sustained release layer
was determined using a USP 24 dissolution testing paddle apparatus (14). The dissolu-
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Table IV. Formulation of the dual component delivery systems
Ingredient Mass of component (mg)
Fast release component










HPMC – hydroxypropyl methylcellulose
MCC – microcrystalline cellulose
tion test was performed using 900 mL of phosphate buffer pH 4.5, at 37 ± 0.5 °C at 50 rpm.
A sample (10 mL) of the solution was withdrawn from the dissolution apparatus hourly
for 12 hours, and the samples were replaced with fresh dissolution medium. The sam-
ples were filtered through a 0.45-mm membrane filter and diluted to a suitable concen-
tration with phosphate buffer pH 4.5. Absorbance of these solutions was measured at
272 nm. Cumulative percentage of drug release was calculated using the equation ob-
tained from a standard curve.
Dissolution profile
The similarity factor (f2) given by SUPAC guidelines (15) for modified release dos-
age forms was used as a basis for comparing dissolution profiles. Dissolution profiles
are considered to be similar when f2 is between 50 to 100. This similarity factor is calcu-
lated by the following formula (16):
n
f2 = 50 ´ log [1+ (1/n)   Rt – Tt  2]–0.5 ´ 100
t=1
where n is the number of experimental points in the in vitro dissolution assay and Rt and
Tt are the mean percentage of dissolved drug from the reference and test formulations.
Kinetic analysis of drug release data
The drug release data was also fitted to the Korsmeyer equation to describe the
drug release from polymeric systems (17, 18).
log (Mt/M∞) = log k + n log t
where Mt is the amount of drug released at time t, M∞ is the amount of drug released
after infinite time, k is a release rate constant incorporating structural and geometric
characterstics of the tablet and n is the diffusional exponent indicative of the mechanism
of drug release. The n value of 1 corresponds to zero-order release kinetics, 0.5 < n < 1
means a non-Fickian release model and n = 0.5 indicates Fickian diffusion (Higuchi
model).
Residence time and aging
The ex vivo residence time was determined using a locally modified USP paddle ap-
paratus (dissolution test apparatus type I) (14). The dissolution medium was composed
of 500 mL phosphate buffer pH 4.5 maintained at 37 ± 0.5 °C. A segment of rabbit intesti-
nal mucosa, 3 cm long, was glued to the surface of a glass slab, vertically attached to the
paddle. The mucoadhesive tablet was hydrated from one surface using 1 to 2 drops of
phosphate buffer and then the hydrated surface was brought into contact with the muco-
sal membrane. The glass slide was vertically fixed to the paddle and allowed rotation at
100 rpm. The time required for complete detachment of the tablet from the mucosal sur-
face was recorded (mean of triplicate determinations) (19). The study was approved by
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the Shree S. K. Patel College of Pharmaceutical Education and Research, Institutional Ani-
mal Ethics Committee.
For the short term stability study, optimized medicated tablets were stored in glass
vials maintained at 40 °C, 75 % RH, for 6 months. The effect of storing was bimonthly in-
vestigated for physical properties, bioadhesive characteristics and the drug release be-
havior.
RESULTS AND DISCUSSION
Fig. 1 demonstrates the FTIR spectra of metoclopramide hydrochloride, HPMC
K100M, Ucarflock 302, microcrystalline cellulose and Ac-di-sol. The FTIR spectrum of me-
toclopramide hydrochloride showed many characteristic peaks of NH-bending,
OH-bending (3199.05, 3301.28, 3410.26 and 3472.95 cm–1), C-H bending (3030.27 cm–1), four
characterestic peaks for N-H stretching (2096.69, 2491.15, 2676.28 and 2706.22 cm–1), C=O
stretching (1598.08 cm–1), CONH stretching (amide) (1538.28 cm–1), asymmetric C-O-C
bending (1271.13 cm–1), C-Cl aromatic stretching (679.93 cm–1). The same characteristic
peaks were observed for the drug-excipient mixture, indicating that no chemical reac-
tion or interaction between the drug and excipients took place.
Prepared dual component tablets were evaluated in terms of various physical pa-
rameters and in vitro dissolution profiles. The average mass of tablets was 1000.0 ± 1.5
mg (n = 20). The drug content in the dual component tablets was 97.7 ± 1.1 %, their
thickness was 3.4 ± 0.1 mm, and their resistance to crushing was 5.4 ± 0.01 kg cm–2. Con-
ventional compressed tablets that lose less than 1 % of weight are generally considered
acceptable. In the present study, the friability was 0.9 ± 0.03 %. Values of the resistance to
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Fig. 1. FTIR spectra of: a) metoclopramide hydrochloride, b) HPMC K100M, c) Ucarflock 302, d)
Ac-di-sol, e) microcrystalline cellulose and f) mixture.
crushing and percent friability indicate good handling properties of the prepared bilayer
tablets. The dissolution data revealed that the formulation containing a larger amount of
HPMC K100M released 87 to 89 % of the drug within 12 h whereas the formulation
contaning a larger amount of Ucarflock 302 released 99 to 100 % of the drug within 12 h.
Thus, it was directly predicted from the drug release profile that the concentration of
HPMC K100M had a significant effect on the drug release rate. The concentration of
polymer was further optimized using a 32 randomized full factorial design.
The drug release profile of factorial batches (F1 to F9) is shown in Fig. 2. It was found
that as the content of HPMC K100M increased, the percentage of drug released decreas-
ed. This might be due to higher swellability of HPMC K100M matrices from the surface
gel layer, so lower penetration of dissolution medium inside the swelled matrices leads
to low availability of fresh dissolution medium inside the matrix and to decreased diffu-
sion of the drug out of matrices.
A 32 full factorial design was constructed to study the effect of the amount of HPMC
K100M (X1) and the amount of Ucarflock 302 (X2) on drug release from the dual compo-
nent tablets. A statistical model incorporating interactive and polynomial terms was uti-
lized to evaluate the response:
Y = b0 + b1 X1 + b2 X2 + b12 X1 X2 + b11 X12 + b22 X22
where Y is the dependent variable, b0 is the arithmetic mean response of nine runs and
b1 is the estimated coefficient for factor X1. The main effects (X1 and X2) represent the ave-
rage results of changing one factor at a time from its low to high value. The interaction
terms (X1X2) show how the response changes when 2 factors are changed simultaneous-
ly. The polynomial terms (X12 and X22) are included to investigate nonlinearity. The t50,
t80, and Q2 values for nine batches (F1 to F9) showed wide variations; results are shown
in Table V. The data clearly indicate that the values of t50, t80, and Q2 are strongly de-
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Fig. 2. In vitro drug release study of factorial design batches (mean ± SD, n = 3).
pendent on the independent variables. The fitted equations (full – YF and reduced – YR)
are shown in the following equations and in Table VI:
YF t50 = 5.798+ 1.321 X1 + 0.516 X2 + 0.007 X12 – 0.183 X22 + 0.047 X1X2
YR t50 = 5.705 + 1.321 X1 + 0.516 X2
(R2 = 0.987)
YF t80 = 9.61 + 1.524 X1 + 0.682 X2 + 0.129 X12 – 0.016 X22 + 0.062 X1X2
YR t80 = 9.64 + 1.524 X1 + 0.682 X2
(R2 = 0.976)
YF Q2 = 22.68 – 10.51 X1 – 4.21 X2 + 3.315 X12 + 3.64 X22 + 0.158 X1X2
YR Q2 = 25.22 – 10.51 X1 – 4.21 X2
(R2 = 0.983)
The polynomial equation can be used to draw conclusions after considering the mag-
nitude of the coefficient and the mathematical sign it carries (i.e., positive or negative).
Table VII shows the results of the analysis of variance (ANOVA), which was performed
to identify insignificant factors. The high values of the coefficient of determination indi-
cate a good fit i.e. good agreement between the dependent and independent variables.
The significance test for the regression coefficients was performed by applying the
Student F-test. A coefficient is significant if the calculated F is greater than the critical
value of F. The results of multiple regression analysis showed that the ratio of HPMC
K100M to Ucarflock 302 had a significant influence on Q2, t50 and t80 (p < 0.05, Tables VI
and VII).
The significance levels of coefficients b12, b11 and b22 were found to be 0.0543, 0.0973
and 0.923, respectively; hence they were omitted from the full model to generate the re-
duced model. The other coefficients were found to be significant at p < 0.05; hence they
were retained in the reduced model. The reduced model was tested partially to deter-
mine whether coefficients b12, b11 and b22 contributed significant information to the pre-
diction of Q2, t50 and t80. The results of partial model testing are shown in Table VII. The
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Table V. Dependent variable from factorial design batches
Batch code Q2 (h) t50 (h) t80 (h)
F1 43.07 3.90 7.51
F2 38.54 4.11 7.91
F3 29.2 4.96 8.91
F4 29.17 5.25 9.16
F5 20.78 6.05 9.86
F6 18.42 6.19 9.94
F7 16.18 6.47 10.27
F8 16.01 6.86 11.03
F9 15.57 7.56 12.18
Checkpoint 18.14 6.55 10.61
282
G. M. Patel and M. M. Patel: Compressed matrix dual-component vaginal drug delivery system containing metoclopramide
hydrochloride, Acta Pharm. 59 (2009) 273–288.
Table VI. Summary of the results of regression analysis
Model Coefficients for Q2
b0 b1 b2 b12 b11 b22 R2
FM 22.68 –10.51 –4.21 3.315 3.64 0.158 0.983
RM 25.22 –10.51 –4.21 0.900
Coefficients for t50
b0 b1 b2 b12 b11 b22 R2
FM 5.798 1.321 0.516 0.007 –0.183 0.047 0.987
RM 5.705 1.321 0.516 0.981
Coefficients for t80
b0 b1 b2 b12 b11 b22 R2
FM 9.61 1.524 0.682 0.129 –0.016 0.062 0.976
RM 9.64 1.524 0.682 0.972
FM – full model
RM – reduced model
Table VII. Calculation for partial testing of the model (ANOVA)
For Q2
Regression DF SS MS F R2
FM 5 839.125 167.825 36.0014 0.9836 Fcal = 5.039
Ftab = 9.28
DF = (3, 3)
RM 2 768.643 384.321 27.2998 0.9009
Error
FM 3 13.9849 4.66163 – –
RM 6 84.4669 14.0778 – –
For t50
Regression DF SS MS F R2
FM 5 12.1329 2.42657 45.6724 0.987 Fcal = 0.453
Ftab = 9.28
DF = (3, 3)
RM 2 12.0607 6.03035 156.263 0.9812
Error
FM 3 0.15939 0.05313 – –
RM 6 0.23155 0.03859 – –
For t80
Regression DF SS MS F R2
FM 5 16.795 3.359 25.4815 0.977 Fcal = 0.188
Ftab = 9.28
DF = (3, 3)
RM 2 16.7208 8.36039 106.804 0.9727
Error
FM 3 0.39546 0.13182 – –
RM 6 0.46967 0.07828 – –
critical value of F for ∞ = 0.05 is equal to 9.28 (df = 3, 3). Since the calculated value for Q2
(F = 5.039) is less than the critical value, it may be concluded that the interaction term b12
and polynomial terms b11 and b22 do not contribute significantly to the prediction of Q2.
The critical value of F for ∞ = 0.05 is equal to 9.28 (df = 3, 3). Since the calculated
value for t50 (F = 0.453) is less then the critical value, it may be concluded that the inter-
action term b12 and polynomial terms b11 and b22 do not contribute significantly to the
prediction of t50. The critical value of F for ∞ = 0.05 is equal to 9.28 (df = 3, 3). Since the
calculated value for t80 (F = 0.188) is less then the critical value, it may be concluded that
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Fig. 3. Contour plots for: a) Q2, b) t50, c) t80, and 3D mesh plot for: d) Q2, e) t50, f) t80.
the interaction term b12 and polynomial terms b11 and b22 do not contribute significantly
to the prediction of t50 and t80, respectively.
An equation containing only statistically significant terms is then used for drawing
contour plots to visualize the impact of changing variables. The optimum point may be
identified from the plot and replicate trials may be run to verify prediction of the opti-
mum response. Figs. 3a–f show the contour plots and 3D mesh plots of the amounts of
HPMC K100M (X1) and of Ucarflock 302 (X2) versus Q2, t50 and t80, respectively. The plot
was drawn using the Sigma Plot software Version 11 (Systat Software, USA).
The data demonstrate that both X1 and X2 affect the drug release (t50 and t80). It may
also be concluded that the low level of X1 (amount of HPMC K100M) and the higher
level of X2 (amount of Ucarflock 302) favour the preparation of dual component vaginal
tablets and that the drug release pattern may be changed by appropriate selection of X1
and X2 levels. Shaded areas in Figs. 3b and 3c (± 5 % level from theoretical value) de-
monstrate the optimized area of individual dependent variables (t50 and t80).
It was arbitrarily decided to select a batch of tablets that release 18–20 % drug
within 2 h. Batches F6 and F7 fall within acceptable criteria. A check point bach was pre-
pared at X1 = – 0.2 and X2 = 0.8. It was expected from the reduced model that t50, t80 and
Q2 values of the check point batch should be 6.65 h, 10.72 h and 17.7 %, respectively. Ta-
ble V shows that the results are as expected. Thus, we can conclude that the statistical
model was mathematically valid.
The results in Table VIII indicate that batches F5, F6 and F7 fulfill the criteria re-
ported by Moore and Flanner (20). However, batch F6 showed the highest f2 (82.6) among
all the batches, and this similarity was also reflected in the t50 value.
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0 0 0 0 0
1 4.65 11.67 10.01 9.14
2 9.3 20.78 18.42 16.18
3 18.66 26.09 25.11 22.04
4 28 33.19 31.48 30.1
5 37.3 41.08 40.17 38.24
6 46.6 50.45 48.12 45.12
7 56 57.24 55.19 51.38
8 65.3 64.57 63.11 60.11
9 74.6 71.19 70.14 67.12
10 83.7 78.01 78.12 74.18
11 93.3 89.05 87.1 86.78
11.5 102.6 98.56 99.79 99.01
f2 59.28 82.68 60.55
Fig. 4 compares the theoretical release profile and dual component system. Dual-
component formulation has shown the ability to maintain a dissolution profile similar to
that of the theoretical release profile, emphasizing their integrity (f2 = 82.6). For the cal-
culation of f2 of the sustained release component, the contribution of metoclopramide
hydrochloride in the immediate release component of the compressed tablet system was
subtracted from the total amount of drug released.
Fig. 5 shows the contributions of each component (fast/prolonged) to the release
profile of metoclopramide hydrochloride from the compressed dual component system
containing a polymer layer as a prolonged release component. According to the figure,
the release profile is characterized by burst release within a few minutes (30 min) fol-
lowed by a slow release period, typical of a biphasic quick/slow delivery system. For
both layers, upon contact with the dissolution media, there was rapid disintegration of
the fast-releasing phase and the sustained release layer released the drug in a predict-
able manner. Prompt tablet disintegration was due to the presence of Ac-di-sol, which
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Fig. 5. Contributions of each component to re-
lease from the dual component system.
swells very quickly when in contact with water. After the initial phase, the release was
dependent on the composition of the sustained release matrix tablet, particularly, the type
and concentration of the polymers. The sustained release tablet kept the metoclopramide
release slow for more than 11 hours.
The drug release data was fitted to the Korsmeyer-Peppas model. From the plot log
(Mt/M∞) vs. log t, n values were close to 1 (n = 1.008, k = 0.915 units), indicating zero-or-
der release kinetics (R2 = 0.998).
The ability of the HPMC K100M and Ucarflock 302 particles to hydrate and form a
gel layer around a core is well known and is essential for sustaining and controlling the
release of a drug from the matrix. Throughout the dissolution test, a continuous gel layer
formed on the surface of the matrix due to hydrophilic polymers HPMC K100M and Ucar-
flock 302. After 12 hours of dissolution testing, it was evident that the gel layer around
the HPMC K100M and Ucarflock 302 cores had retained its integrity, exhibiting a porous
structure when observed under an optical microscope.
The results obtained from the ex vivo residence time revealed that higher polymer
swelling at the interface enabled better interpenetration and entanglement and conse-
quently stronger mucoadhesion. The residence time (the time required for complete tab-
let detachment) of the optimized formulation was 12.2 h. From this result, it was pre-
dicted that the optimized formulation had the desired residency ex vivo.
The effect of aging was studied for the optimized formulation containing 30 mg of
the drug. The data shown in Table IX reveal no marked change in resistance to crushing,
drug content and in vitro drug release (5.4 kg cm–2, 99.0 % and 98.1 % after 6 months) re-
spectively. A reduction in residence time was noticed approximately 10 min for stored
formulation compared to the fresh one. The constant n value (1.008 to 1.000 after 6
months) reveals that the release from the dual component mucoadhesive system is not
affected by storage.
CONCLUSIONS
A dual-component vaginal quick/slow delivery system was achieved, characterized
by an initial rapid release phase corresponding to the drug present in the immediate re-
lease layer, followed by a period of slow release, corresponding to the drug from the
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Table IX. Short-term stability data of the mucoadhesive dual component tablet
Duration of storage (month)
Characteristics 0 1 3 6
Resistance to crushing (kg cm–2) 5.5 ± 0.1 5.5 ± 0.1 5.4 ± 0.1 5.4 ± 0.1
Drug content (%) 99.57 99.12 99.13 98.99
Ex vivo residence time (h) 12.5 12.5 12.5 12.2
Drug released (%) 99.5 99.5 99.1 98.9
t50 (h) 5.73 5.70 5.70 5.71
Release kinetics (n) 1.008 1.001 1.000 1.000
sustained release layer. The design of the two different release phases can be easily ad-
justed in both the delivery rate and the ratio of dose fractions to the pharmacokinetics
and therapeutic needs, to provide the desired in vitro profile. The results obtained with
the dissolution test show that the release profile is dependent on both the type and amount
of polymer in the sustained release layer. After immediate release of metoclopramide
hydrochloride, both types of polymers (HPMC K100M and Ucarflock 302) were able to
modulate the metoclopramide hydrochloride release for a prolonged time (almost 11 to
12 h) with a dissolution profile similar to that of the theoretical release profile. Based on
the f2 value, this suggests their integrity after compaction, indicating the promising po-
tential of the metoclopramide hydrochloride biphasic vaginal tablet as an alternative to
the conventional dosage form.
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S A @ E T A K
Komprimirani matriksni dvokomponentni sustavi s metoklopramid hidrokloridom
GEETA M. PATEL i MADHABHAI M. PATEL
Cilj rada bila je priprava brzog/sporog bifazi~nog sustava za isporuku metoklopramid
hidroklorida koriste}i dezintegrator Ac-di-sol za sloj koji brzo osloba|a i hidroksipropil
metilcelulozu K100M i Ucarflock 302 za moduliranje osloba|anja ljekovite tvari. Dvo-
komponentna tableta sa slojem za usporeno i slojem za brzo osloba|anje pripravljena je
metodom izravne kompresije. 32 faktorijalni dizajn primijenjen je za sistematsko optimi-
ranje profila osloba|anja ljekovite tvari u sloju za usporeno osloba|anje. Rezultati ukazu-
ju na to da su mala koli~ina HPMC K100M i velika koli~ina Ucarflock 302 bitne za usporeno
osloba|anje metoklopramid hidroklorida u dvokomponentnom sustavu za vaginalnu
upotrebu. Ex vivo ispitivanja pokazuju da se pripravak zadr`ava vi{e od 10 h. Naglo oslo-
ba|anje lijeka omogu}ava brzo postizanje udarne doze, a postupno osloba|anje tijekom
12 h odr`avanje u~inkovite koncentracije, ~ime se rje{ava problem opetovane primjene,
posebno u trudno}i.
Klju~ne rije~i: dvokomponentni sustav, mukoadhezija, faktorijalni dizajn, brzo/sporo osloba|anje,
vaginalna primjena
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